317 studies found for:    Open Studies | "Triplets"
Show Display Options
Rank Status Study
21 Recruiting HSP90 Inhibitor AT13387 and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Hsp90 Inhibitor AT13387;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Pharmacological Study
22 Recruiting Romidepsin Plus Cisplatin in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
Conditions: Triple-Negative Breast Cancer;   Breast Cancer
Interventions: Drug: Romidepsin;   Drug: Cisplatin
23 Recruiting Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Cisplatin
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Intervention: Other: Laboratory Biomarker Analysis
24 Recruiting Palbociclib in Treating Patients With Metastatic HER-2 Positive or Triple-Negative Breast Cancer With Brain Metastasis
Conditions: Breast Carcinoma Metastatic in the Brain;   Estrogen Receptor Negative;   HER2/Neu Negative;   HER2/Neu Positive;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Procedure: Cognitive Assessment;   Drug: Palbociclib;   Procedure: Quality-of-Life Assessment;   Biological: Trastuzumab
25 Recruiting Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Galunisertib;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
26 Recruiting Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Condition: Triple Negative Breast Cancer
Intervention: Drug: GTx-024
27 Recruiting Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Akt Inhibitor GSK2141795;   Other: Laboratory Biomarker Analysis;   Drug: Trametinib
28 Not yet recruiting Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Interventions: Drug: Drug: Selumetinib;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Docetaxel
29 Recruiting Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer (KEYNOTE-162)
Conditions: Triple Negative Breast Cancer;   Ovarian Cancer;   Breast Cancer;   Metastatic Breast Cancer;   Advanced Breast Cancer;   Stage IV Breast Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Interventions: Drug: niraparib;   Biological: pembrolizumab
30 Not yet recruiting Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients
Conditions: Breast Cancer;   Metastatic Triple Negative
Interventions: Drug: Pembrolizumab;   Radiation: Radiotherapy
31 Recruiting Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
Conditions: Inflammatory Breast Cancer;   Stage IIA Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer;   Stage IIB Breast Cancer;   Estrogen Receptor Negative;   Progesterone Receptor Negative;   HER2/Neu Negative
Interventions: Drug: carboplatin;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Other: laboratory biomarker analysis
32 Recruiting Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
Conditions: Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
33 Recruiting Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients
Conditions: Triple-Negative Invasive Breast Carcinoma;   Residual Tumor
Interventions: Drug: Carmustine;   Drug: Cyclophosphamide;   Drug: Carboplatin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation
34 Not yet recruiting Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer
Conditions: Adult Solid Neoplasm;   Estrogen Receptor Negative;   Fallopian Tube Serous Neoplasm;   HER2/Neu Negative;   Ovarian Serous Adenocarcinoma;   Ovarian Serous Tumor;   Primary Peritoneal Serous Adenocarcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Triple-Negative Breast Carcinoma
Interventions: Drug: Hsp90 Inhibitor AT13387;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Talazoparib
35 Recruiting Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
Condition: Metastatic Triple Negative Breast Cancer
Interventions: Biological: pembrolizumab;   Drug: capecitabine;   Drug: eribulin;   Drug: gemcitaine;   Drug: vinorelbine
36 Recruiting Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)
Condition: Advanced Triple Negative Breast Cancer (TNBC) With High TAMs
Interventions: Drug: MCS110;   Drug: carboplatin;   Drug: gemcitabine
37 Recruiting Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy
Condition: Locally Recurrent/Metastatic Triple Negative Breast Cancer
Interventions: Radiation: external beam radiation therapy;   Drug: cisplatin;   Procedure: Biopsy of Target Tumor
38 Recruiting A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple Negative Breast Cancer (IMpassion130)
Condition: Metastatic Breast Cancer, Triple Negative Breast Cancer
Interventions: Drug: Atezolizumab;   Drug: Nab-Paclitaxel;   Drug: Placebo
39 Not yet recruiting The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer
Condition: Triple Negative Breast Neoplasms
Interventions: Drug: Chemo;   Biological: Immunotherapy
40 Recruiting A Pilot Surveillance Study to Monitor Natural Killer Cells and Circulating Tumor Cells in Women With Previously Treated Non-metastatic Triple Negative Breast Cancer and Women With Previously Treated Non-metastatic Breast Cancer With a Confirmed BRCA Mutation.
Conditions: Triple Negative Breast Cancer;   Natural Killer Cells;   BRCA Mutation
Intervention: Device: LiquidBiopsy®, NK VueTM

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years